PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist studied for CNS-mediated sexual arousal pathways, melanocortin signaling, and appetite research.
| Molecular Weight | 1025.21 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide that was developed from Melanotan II. It is unique among peptides because it acts directly on the central nervous system (CNS) to modulate sexual response and desire.
PT-141 works by binding to melanocortin receptors in the brain, specifically the MC3 and MC4 receptors. Unlike traditional treatments for sexual dysfunction that act on the vascular system, PT-141 triggers the neural pathways responsible for sexual arousal and libido.
Research into PT-141 has shown it to be effective in both males and females for treating hypoactive sexual desire disorder (HSDD) and erectile dysfunction. It is a major subject of study for its ability to restore sexual function in research models where traditional vascular treatments have failed.